Simplify Asset Management Inc. Takes Position in SAB Biotherapeutics, Inc. $SABS

Posted by Geri Gentry on May 25th, 2026

Simplify Asset Management Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 208,227 shares of the company’s stock, valued at approximately $779,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new position in SAB Biotherapeutics during the 3rd quarter worth $30,000. Dimensional Fund Advisors LP bought a new position in shares of SAB Biotherapeutics during the third quarter worth about $32,000. Virtu Financial LLC bought a new position in shares of SAB Biotherapeutics during the third quarter worth about $40,000. Jefferies Financial Group Inc. acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter worth about $2,170,000. Finally, Woodline Partners LP bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at about $5,730,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $3.90 on Monday. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $3.83 and its 200 day moving average price is $3.85. SAB Biotherapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $6.60. The firm has a market cap of $298.21 million, a P/E ratio of -1.85 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, sell-side analysts predict that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SABS. Citigroup assumed coverage on shares of SAB Biotherapeutics in a research note on Friday. They set a “buy” rating and a $11.00 target price for the company. Chardan Capital lifted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Rodman & Renshaw restated a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.00.

Get Our Latest Stock Analysis on SAB Biotherapeutics

SAB Biotherapeutics Company Profile

(Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.